Conclusions No conclusive recommendations were possible due to wide variation in study quality , method ologies and outcome measures .
A synthesis of available literature suggests that treatments containing urea as a primary active ingredient have been the most research ed .
Background Xerosis , literally dryness of the skin , of the foot is a common condition encountered clinical ly , which can lead to discomfort and predisposition to infection .
Currently , there are no evidence -based recommendations on which moisturiser formulations best alleviate xerotic symptoms .
The aim of this review was to guide clinical practice in the treatment of primary and diabetes related foot xerosis , by identifying from the existing literature the most effective ingredient or formulation of topical treatments for symptoms of primary foot xerosis in the general population .
Evaluation of the moisturizer Pédimed(®) in the foot care of diabetic patients.
AIM Xerosis is one of the most common abnormalities observed in the diabetic foot , promoting ulceration through the development of fissures and hyperkeratosis . Its treatment is therefore paramount and must be implemented early on . The objective of this study was to assess the moisturizing properties of Pédimed ( ® ) cream in the treatment of foot xerosis in diabetic patients . METHODS In this r and omized double-blind study , Pédimed ( ® ) and its placebo were r and omly allocated to the right/left foot of each patient ( one active/one control side ) . Products were applied twice daily for 4 weeks . Xerosis was assessed using the clinical Xerosis Assessment Scale ( XAS ) , corneometry ( skin hydration measurement ) and D-Squame ( ® ) ( scale sample analysis ) after 14 ( D14 ) and 28 ( D28 ) days of treatment . RESULTS Twenty-four men and 30 women , aged 57.0±12.7 years , with type 1 or type 2 diabetes and moderate-to-severe foot xerosis were included . A dramatic decrease in XAS score that was more marked with Pédimed ( ® ) than with placebo was observed from D14 ( 38.1 % vs 20.9 % , P<0.0001 ) , reaching 61.9 % vs 34.9 % at D28 ( P<0.0001 ) . The number of feet with fissures was greatly reduced with Pédimed ( ® ) compared with placebo at both D14 ( 11.1 % vs 22.2 % , P=0.031 ) and D28 ( 5.6 % vs 18.5 % , P=0.039 ) . Skin hydration increased by 48.9 % with Pédimed ( ® ) vs 31.7 % with placebo at D14 ( P=0.0002 ) , reaching 57.3 % vs 36.5 % at D28 ( P<0.0001 ) . All D-Squame ( ® ) parameters showed greater improvement with Pédimed ( ® ) . Product tolerability was excellent . CONCLUSION Vali date d clinical and para clinical tools demonstrated the efficacy  of Pédimed ( ® ) in improving xerosis and reducing fissures of the feet in diabetic patients
Conclusions No conclusive recommendations were possible due to wide variation in study quality , method ologies and outcome measures .
A synthesis of available literature suggests that treatments containing urea as a primary active ingredient have been the most research ed .
Background Xerosis , literally dryness of the skin , of the foot is a common condition encountered clinical ly , which can lead to discomfort and predisposition to infection .
Currently , there are no evidence -based recommendations on which moisturiser formulations best alleviate xerotic symptoms .
The aim of this review was to guide clinical practice in the treatment of primary and diabetes related foot xerosis , by identifying from the existing literature the most effective ingredient or formulation of topical treatments for symptoms of primary foot xerosis in the general population .